|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Celecoxib (CEL) is a selective cyclooxygenase-2 (COX-2) inhibitor therapeutically indicated for the treatment of rheumatoid arthritis, osteoarthritis, acute pain, and inflammation.
|
30347274 |
2019 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Celecoxib is a selective cyclooxygenase-2 inhibitor widely used in patients with osteoarthritis and rheumatoid arthritis.
|
31564512 |
2019 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The mRNA expression of antioxidant enzymes such as MnSOD, Cu/ZnSOD, ECSOD, CAT, and GPx1 was found to be downregulated, whereas COX-2 was upregulated in RA rats; however, the mRNA expression of CAT, GPx1, and COX-2 reverted back to near normal levels in SeNPs-treated animals.
|
30718447 |
2019 |
|
Rheumatoid Arthritis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Cox proportional hazard regression analysis revealed the lower rate of admission for subjects under combination therapy (adjusted hazard ratio of 0.275; 95% confidence interval = 0.136-0.557, P < .001).Patients with RA and T2DM receiving the combination of COX-2 inhibitors and metformin were associated with lower admission rate than those on COX-2 inhibitors alone, and this effect may be attributed to the decrease in the levels of proinflammatory factors.
|
31593087 |
2019 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, ASE could suppress the mRNA expression of COX-2 and CHI3L1 and improve the mRNA expression of CAT and GPx-1 in ankle tissues of RA rats.<b>Discussion and conclusions:</b> For the first time, our results indicated ASE exerts anti-RA effects via inhibiting pro-inflammatory factors and alleviating oxidative stress.
|
31747811 |
2019 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus, elevated COX-2 expression in subchondral bone induces both OA-associated and RA-associated joint cartilage degeneration.
|
31666999 |
2019 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Celecoxib (CXB), a COX-2 inhibitor, is primarily indicated for long-term treatment of rheumatoid arthritis (RA).
|
30143947 |
2018 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Tetrandrine alleviates symptoms of rheumatoid arthritis in rats by regulating the expression of cyclooxygenase-2 and inflammatory factors.
|
30186500 |
2018 |
|
Rheumatoid Arthritis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Corticosteroids (OR = 1.26) and NSAIDs (nonselective NSAIDs: OR = 1.32, Cox-2 inhibitors: OR = 1.31) were risk factors for CVD in RA patients.
|
28863826 |
2018 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Effects of human cyclooxygenase-2 gene silencing on synovial cells of rheumatoid arthritis mediated by lentivirus.
|
30314410 |
2018 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the exact cause of RA is not known but the complex interaction between inflammatory mediators like tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), cyclooxygenase-2 (COX-2) and nitric oxide (NO) is accountable for cartilage destruction in joints.
|
29553845 |
2018 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Indomethacin (IDMT), a non-selective inhibitor of cycloxygenase-2 (COX-2), plays important roles in anti-inflammation and analgesia and it is commonly used to treat the patients with rheumatic and rheumatoid arthritis.
|
30119183 |
2018 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus, our results verified the co-occurrence of RA and periodontal inflammation using experimental mouse models of RA, suggesting that iNAMPT in PDL cells plays a pivotal role in the pathogenesis of RA-mediated periodontal inflammation by regulating the expression levels of catabolic genes, such as IL6, IL8, CCL5, COX-2, MMP1, and MMP3.
|
28165872 |
2017 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF-induced mRNA stabilization in RA FLS occurs during the late phase of TNF response, is MAPK-dependent, and involves several genes with pathogenic potential such as IL6, CXCL1, CXCL3, CXCL8/IL8, CCL2, and PTGS2.
|
28708839 |
2017 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we investigated the mechanisms underlying BK-induced COX-2 expression which is modulated by resveratrol/Sirt1 in human rheumatoid arthritis synovial fibroblasts (RASFs).
|
28288820 |
2017 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that TXNDC5 is directly targeted by microRNA (miR)-573, and TXNDC5, in turn, mediates the suppressive effect of miR-573 on the invasion of synovial fibroblasts of RA (RASFs). miR-573 overexpression suppressed the expression of interleukin 6 (IL-6) and cyclooxygenase 2 in RASFs, as well as the production of tumor necrosis factor-alpha and interleukin-1 beta by activated THP-1 cells in response to lipopolysaccharide (LPS) stimulation.
|
26166764 |
2016 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Morphological observations revealed that the number of inflammatory cells were reduced and damage to tendon fibers was attenuated in this group, suggesting that the downregulation of the protein expression levels of TNF‑α‑associated nuclear factor‑κB, matrix metalloproteinase (MMP)1, MMP9, cyclooxygenase (COX)‑1 and COX‑2 may exert a therapeutic effect on inflammation of the SAB caused by rheumatoid arthritis.
|
26130073 |
2015 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated synovial COX-2 expression facilitates the pathogenesis of OA and RA, and thus this index reflects the condition of these 2 diseases.
|
26505439 |
2015 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Treatment of RA FLS with GW3965 induced dose-dependent reductions in mRNA expression of pro-inflammatory mediators (IL-1β, IL-6, MMP-9, CCL-2, CCL-7, and COX-2).
|
22990668 |
2013 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results indicate that kaempferol inhibits synovial fibroblast proliferation, as well as the production of and MMPs, COX‑2 and PGE2, which is involved in articular inflammation and destruction in rheumatoid arthritis (RA).
|
23934131 |
2013 |
|
Rheumatoid Arthritis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Enhancement of PLGF production by 15-(S)-HETE via PI3K-Akt, NF-κB and COX-2 pathways in rheumatoid arthritis synovial fibroblast.
|
23872401 |
2013 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results indicate that quercetin inhibits synovial fibroblasts proliferation and MMPs, COX-2, and PGE2 production, which involved joint destruction in rheumatoid arthritis (RA), and suggest that it might be a new therapeutic agent for management of RA.
|
22592909 |
2012 |
|
Rheumatoid Arthritis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphism -765 G/C in COX-2-encoding gene promoter is associated with development of Alzheimer's disease, depression, carcinoma of the pancreas in smokers, breast cancer and rheumatoid arthritis.
|
21655952 |
2012 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Conventional medical treatment for rheumatoid arthritis and osteoarthritis includes the use of NSAIDs (traditional and selective inhibitors of cyclooxygenase [COX]-2), because they provide unmistakable and significant health benefits in the treatment of pain and inflammation.
|
22114888 |
2011 |
|
Rheumatoid Arthritis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, sPLA(2)-IIA regulates AA flux through the cPLA(2)-α/COX-2 pathway in RA FLSs by up-regulating steady state levels of these biosynthetic enzymes through an indirect mechanism, rather than direct provision of substrate to the pathway.
|
21068383 |
2011 |